Live Breaking News & Updates on Davida Sallman

Stay updated with breaking news from Davida sallman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Early Efficacy With Fedratinib in MDS/MPN and CNL Warrants Its Continued Evaluation

David A. Sallman, MD, discusses the potential use of fedratinib to manage symptomatic myelodysplastic syndrome/myeloproliferative neoplasms. ....

United States , Davida Sallman , International Working Group , Malignant Hematology , Moffitt Cancer Center ,

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia. ....

Davida Sallman , Moffitt Cancer Center , Department Of Malignant Hematology , Malignant Hematology , Moffitt Cancer Center , Onclive Tv , Myeloproliferative Neoplasms , Hematologic Oncology , Myelodysplastic Syndromes , Myeloproliferative Neoplasm ,

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006. ....

United States , Davida Sallman , Steven Harasym , Helen Sabzevari , Exchange Commission , International Prognostic Scoring System , American Cancer Society , Precigen Inc , Dose Level , Bone Marrow , Stable Disease , European Leukemianet , Objective Responses , Control Rate , Response Rate , Summary Data , Complete Response , Advancing Medicine , Acute Myeloid Leukemia , Myelodysplastic Syndrome , Sleeping Beauty , Annual Report , Key Statistics ,

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

UCART22: anti-tumor activity observed in 60% of patients at DL3 using FCA lymphodepletionUCART123: 25% of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a. | December 13, 2022 ....

New York , United States , France General , North Carolina , Noord Holland , Ashleyr Robinson , Davida Sallman , Mark Frattini , Nitin Jain , Arthur Stril , Cellecti Adss , Margaret Gandolfo , Pascalyne Wilson , Securities Exchange Commission , University Of Texas Md Anderson Cancer Center , Moffit Cancer Center , Amsterdam University Medical Center Vumc , Meeting Of The American Society Hematology , Department Of Leukemia , Department Of Malignant Hematology , Company Euronext Growth , Euronext Growth , Annual Meeting , American Society , Natural Killer , Cancer Center ,

Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS

About a third of patients, including those with <em>TP53</em> mutations, achieved complete remission ....

United States , Davida Sallman , Mike Bassett , University Of Texas Md Anderson Cancer Center , International Prognostic Scoring System , Moffitt Cancer Center , Society Of Hematologic Oncology , Naval Daver , Cancer Center , Hematologic Oncology ,